about
Assessment of nutrient supplement to reduce gentamicin-induced ototoxicity.Renal magnification by EGFAdverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative studyLower incidence of hypo-magnesemia in surgical intensive care unit patients in 2011 versus 2001Effect of mycophenolate mofetil on plasma bioelements in renal transplant recipients.Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosisProton pump inhibitor associated hypomagnasaemia - a cause for concern?Frequency and Associated Factors of Amphotericin B Nephrotoxicity in Hospitalized Patients in Hematology-Oncology Wards in the Southwest of IranDiuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy.How should hypomagnesaemia be investigated and treated?Magnesium disorders: clinical experience and review of the literature.Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.Contemporary view of the clinical relevance of magnesium homeostasis.Posterior reversible encephalopathy syndrome with colitis in a patient treated with panitumumab.The association of proton pump inhibitors and hypomagnesemia in the community setting.Characterizing the effect of pentamidine isethionate on the immune system using mouse splenocytes as an experimental model.N-acetyl cysteine in prevention of amphotericin- induced electrolytes imbalances: a randomized, double-blinded, placebo-controlled, clinical trial.Acute-onset hypomagnesemia-induced hypocalcemia caused by the refractoriness of bones and renal tubules to parathyroid hormone.Magnesium and Human Health: Perspectives and Research Directions.
P2860
Q30410332-64958026-7632-4D2E-96BC-4BA5B7153EB6Q33724385-4FFB5AA4-64B1-41F7-967A-CA0A77B0E2BEQ33913102-B983AD81-2EED-4557-8A7A-635D61EB94F1Q35087936-0FB8F8F7-95F3-465D-BC73-11B44C863A81Q35737431-EF73BBF1-637A-46CB-A37E-8DB8F23D0E5DQ36237958-76261901-A909-4416-9768-35D88E1A8EFBQ36706785-61BD2F51-8726-4180-AB8E-D14520FDFDD5Q37428868-032E9AC2-7020-42B4-A876-A183849BFBBFQ37679929-3E708735-35CE-4C0C-9187-F08885577310Q37875204-9C60E09C-0B60-426A-B1F6-2578A0467392Q37998434-BC84A42D-EFE4-4DDB-8E91-0051B33BF3F4Q38077678-975DE621-8F4F-4242-89B8-02909B5598DAQ38176746-81620D23-B470-4B26-9146-6645051C4489Q42291179-95D32545-3E5C-44CB-8581-82D657CBC7BFQ44104361-A5471EF8-24EF-42FF-B195-9DA6A31A161AQ44203247-8B4B27C3-086B-4C29-A84F-ED60930BD3A8Q44596376-2F25FF42-9C76-4E5A-B994-1B73707D2046Q45361894-390ED507-198B-4EB8-BD3F-922C4E108310Q55396565-3A116767-6248-483E-A771-9CDE47771A13
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Drug-induced hypomagnesaemia : scope and management.
@ast
Drug-induced hypomagnesaemia : scope and management.
@en
type
label
Drug-induced hypomagnesaemia : scope and management.
@ast
Drug-induced hypomagnesaemia : scope and management.
@en
prefLabel
Drug-induced hypomagnesaemia : scope and management.
@ast
Drug-induced hypomagnesaemia : scope and management.
@en
P2860
P1433
P1476
Drug-induced hypomagnesaemia : scope and management.
@en
P2093
Eran Dolev
Jacob Atsmon
P2860
P304
P356
10.2165/00002018-200528090-00003
P577
2005-01-01T00:00:00Z
P6179
1013616570